Cart
sales@molnova.com
Pritelivir
CAS No. 348086-71-5
Pritelivir( BAY 57-1293 | AIC316 )
Catalog No. M17491 CAS No. 348086-71-5
Pritelivir (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 35 | In Stock |
|
| 10MG | 50 | In Stock |
|
| 25MG | 79 | In Stock |
|
| 50MG | 110 | In Stock |
|
| 100MG | 177 | In Stock |
|
| 500MG | 440 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePritelivir
-
NoteResearch use only, not for human use.
-
Brief DescriptionPritelivir (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).
-
DescriptionPritelivir (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).(In Vivo):Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex.Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis.Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS.
-
In Vitro——
-
In VivoPritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex. Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis. Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS. Animal Model:Female BALB/c mice Dosage:0.03 to 45 mg/kg Administration:Administered orally, twice daily at approximately 12 h intervals, for 7 days Result:Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%.
-
SynonymsBAY 57-1293 | AIC316
-
PathwayImmunology/Inflammation
-
TargetAntiviral
-
Recptorhelicase primase
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number348086-71-5
-
Formula Weight402.49
-
Molecular FormulaC18H18N4O3S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 33 mg/mL; 81.99 mM
-
SMILESCc1c(sc(n1)N(C)C(=O)Cc1ccc(cc1)c1ccccn1)S(=O)(=O)N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kleymann G, et al. Nat Med. 2002, 8(4), 392-398.
molnova catalog
related products
-
(R,1R)-Tenofovir ami...
(R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) is an orally administered Tenofovir prodrug with antiviral activity. Tenofovir is a nucleotide reverse transcriptase inhibitor.
-
Aristeromycin
Aristeromycin (U 99468) is a broad-spectrum antiviral antibiotic that targets RNA viruses and is an inhibitor of S-adenosylhomocysteine hydrolase (AHCY).
-
Arg-AMS
Arg-AMS is an arginine tRNA synthetase inhibitor with antiviral activity that targets the host protein CD163 to inhibit porcine blue ear virus and the highly pathogenic strain HP-PRRSV, and can be used to study viral infections and myeloma.
